LUND, Sweden, April 8, 2020 /PRNewswire/ -- BioInvent International AB (publ) (BINV) today announced that the Annual Report for 2019 is available at the company's website, www.bioinvent.com
About BioInvent
BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively. Two preclinical programs in solid tumors are expected to have entered clinical trials by the end of 2020. The Company's validated, proprietary F.I.R.S.T technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.
For further information, please contact: | |
Martin Welschof, CEO |
Hans Herklots, LifeSci Advisors |
+46 (0)46 286 85 50 |
+41 79 598 71 49 |
martin.welschof@bioinvent.com | hherklots@lifesciadvisors.com |
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
This information is information that BioInvent International AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 12.30 p.m. CET on April 8, 2020.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://mb.cision.com/Main/583/3084336/1226821.pdf | Annual Report (PDF) |
https://mb.cision.com/Public/583/3084336/a4f7085dde124f83.pdf | Press release (PDF) |
